CANCER CONTROL FRANCOPHONE 2021 37
FACTEURS DE RISQUE
46. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a
polymicrobial disease? Nat Rev Microbiol. févr 2005;3(2):182-7.
47. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, et al. Endemic
Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction
between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol. déc
2009;19(6):411-20.
48. Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, et al. A
molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathogens.
2007;3(6):0826-34.
49. Donati D, Zhang LP, Chêne A, Chen Q, Flick K, Nyström M, et al. Identification
of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun. sept
2004;72(9):5412-8.
50. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, et al.
Serological evidence for long-term Epstein-Barr virus reactivation in children living in a
holoendemic malaria region of Kenya. J Med Virol. juin 2009;81(6):1088-93.
51. Chattopadhyay PK, Chelimo K, Embury PB, Mulama DH, Sumba PO, Gostick E, et al.
Holoendemic Malaria Exposure Is Associated with Altered Epstein-Barr Virus-Specific
CD8+ T-Cell Differentiation. Journal of Virology. 2013;87(3):1779-88.
52. Snider CJ, Cole SR, Chelimo K, Sumba PO, Macdonald PDM, John CC, et al. Recurrent
Plasmodium falciparum malaria infections in Kenyan children diminish T-cell immunity
to Epstein Barr virus lytic but not latent antigens. PLoS One. 2012;7(3):e31753.
53. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, et al. Malaria
hemozoin is immunologically inert but radically enhances innate responses by
presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A. 6 févr
2007;104(6):1919-24.
54. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, et al. CpG drives
human transitional B cells to terminal differentiation and production of natural
antibodies. J Immunol. 15 janv 2008;180(2):800-8.
55. Potup P, Kumsiri R, Kano S, Kalambaheti T, Looareesuwan S, Troye-Blomberg M,
et al. Blood stage Plasmodium falciparum antigens induce immunoglobulin class
switching in human enriched B cell culture. Southeast Asian J Trop Med Public Health. juill
2009;40(4):651-64.
56. MacNeil A, Sumba OP, Lutzke ML, Moormann A, Rochford R. Activation of the
Epstein-Barr virus lytic cycle by the latex of the plant Euphorbia tirucalli. Br J Cancer. 19
mai 2003;88(10):1566-9.
57. van den Bosch C, Griffin BE, Kazembe P, Dziweni C, Kadzamira L. Are plant factors a
missing link in the evolution of endemic Burkitt's lymphoma? British journal of cancer.
1993;68(6):1232-5.
58. Osato T, Mizuno F, Imai S, Aya T, Koizumi S, Kinoshita T, et al. African Burkitt's
lymphoma and an Epstein-Barr virus-enhancing plant Euphorbia tirucalli. Lancet. 30
mai 1987;1(8544):1257-8.
59. Mizuno F, Osato T, Imai S, Koizumi S, Aya T, Kinoshita T, et al. Epstein-Barr virusenhancing plant promoters in east Africa. AIDS
Res. déc 1986;2 Suppl 1:S151-155.
60. Osato T, Imai S, Kinoshita T, Aya T, Sugiura M, Koizumi S, et al. Epstein-Barr
virus, Burkitt's lymphoma, and an African tumor promoter. Adv Exp Med Biol.
1990;278:147-50.
61. Ito Y, Kawanishi M, Harayama T, Takabayashi S. Combined effect of the extracts from
Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on EpsteinBarr virus expression
in human lymphoblastoid P3HR-1 and Raji cells. Cancer Lett. avr
1981;12(3):175-80.
62. Mizuno F, Koizumi S, Osato T, Kokwaro JO, Ito Y. Chinese and African Euphorbiaceae
plant extracts: Markedly enhancing effect on Epstein-Barr virus-induced
transformation. Cancer Letters. 1983;19(2):199-205.
63. Mannucci S, Luzzi A, Carugi A, Gozzetti A, Lazzi S, Malagnino V, et al. EBV reactivation
and chromosomal polysomies: Euphorbia tirucalli as a possible cofactor in endemic
Burkitt lymphoma. Advances in Hematology. 2012;
64. Imai S, Sugiura M, Mizuno F, Ohigashi H, Koshimizu K, Chiba S, et al. African Burkitt's
lymphoma: a plant, Euphorbia tirucalli, reduces Epstein-Barr virus-specific cellular
immunity. Anticancer Res. juin 1994;14(3A):933-6.
65.Steel CM, Morten JE, Foster E. The cytogenetics of human B lymphoid malignancy:
studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
lines. IARC Sci Publ. 1985;(60):265-92.
66. Aya T, Kinoshita T, Imai S, Koizumi S, Mizuno F, Osato T, et al. Chromosome
translocation and c-MYC activation by Epstein-Barr virus and Euphorbia tirucalli in B
lymphocytes. Lancet. 1991;337(8751):1190.
67. Xu Y, Gong YY, Routledge MN. Aflatoxin exposure assessed by aflatoxin albumin
adduct biomarker in populations from six African countries. Vol. 11. 2018. 411-419 p.
68. Passarelli S, Bromage S, Darling AM, Wang J-S, Aboud S, Mugusi F, et al. Aflatoxin
exposure in utero and birth and growth outcomes in Tanzania. Matern Child Nutr. avr
2020;16(2):e12917.
69. Turner PC, Collinson AC, Cheung YB, Gong Y, Hall AJ, Prentice AM, et al. Aflatoxin
exposure in utero causes growth faltering in Gambian infants. Int J Epidemiol. oct
2007;36(5):1119-25.
70. Hernandez-Vargas H, Castelino J, Silver MJ, Dominguez-Salas P, Cros MP, Durand
G, et al. Exposure to aflatoxin B1 in Utero is associated with DNA methylation in
white blood cells of infants in The Gambia. International Journal of Epidemiology.
2015;44(4):1238-48.
71. Lauer JM, Duggan CP, Ausman LM, Griffiths JK, Webb P, Wang J-S, et al. Maternal
aflatoxin exposure during pregnancy and adverse birth outcomes in Uganda. Matern
Child Nutr. avr 2019;15(2):e12701.
72. IARC IA for R on C. Monographs on the Evaluation of Carcinogenic Risks to Humans.
In: The Monographs [Internet]. 2002. p. 171-300. Disponible sur: http://monographs.
iarc.fr
73. Marchese S, Polo A, Ariano A, Velotto S, Costantini S, Severino L. Aflatoxin B1 and
M1: Biological properties and their involvement in cancer development. Vol. 10. 2018.
74. Accardi R, Gruffat H, Sirand C, Fusil F, Gheit T, Hernandez-Vargas H, et al. The
mycotoxin aflatoxin B1 stimulates Epstein-Barr virus-induced B-cell transformation in
in vitro and in vivo experimental models. Carcinogenesis. nov 2015;36(11):1440-51.
75. Preisler V. Aflatoxin B1-induced mitotic recombination in L5178Y mouse lymphoma
cells. Mutagenesis. 2000;15(1):91-7.
76. International Agency for Research on Cancer. Aflatoxins IARC Monographs.
International agency for Research on Cancer. 2012;100F:225-48.
77. Rushing BR, Selim MI. Aflatoxin B1: A review on metabolism, toxicity, occurrence in
food, occupational exposure, and detoxification methods. Vol. 124. 2019. 81-100 p.
78. Engin AB, Engin A. DNA damage checkpoint response to aflatoxin B1. Vol. 65. 2019.
90-96 p.